Provided by Tiger Fintech (Singapore) Pte. Ltd.

NLS Pharmaceutics Ltd.

7.62
0.0000
Volume:- -
Turnover:- -
Market Cap:32.40M
PE:- -
High:7.62
Open:7.62
Low:7.62
Close:7.62
52wk High:7.62
52wk Low:0.7400
Shares:4.25M
Float Shares:3.42M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.6288
ROE:-862.92%
ROA:-75.98%
PB:11.50
PE(LYR):-2.90

Loading ...

Company Profile

Company Name:
NLS Pharmaceutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
- -
Office Location:
The Circle 6,Zurich,Zurich,Switzerland
Zip Code:
8058
Fax:
41 44 512 21 51
Introduction:
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.